$ABUS The ‘069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins. LNP technology is crucial to Moderna’s vaccine development efforts, and the patent ruling could increase pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus’ patent portfolio, said Zachary Silbersher, a patent lawyer in New York not involved the case. Silbersher said it was unclear if vaccines being developed by Moderna, including its coronavirus vaccine, infringe the ‘069 patent and related ones owned by Arbutus. But Moderna’s effort to invalidate the patent suggests the company sees it as a potential obstacle, he said. “At the end of the day, Arbutus might be able to claim a royalty in the [coronavirus] vaccine,” Silbersher said.